Sevelamer Carbonate Tablets Combined with Hemodialysis in the Therapy of Uremia with Hyperphosphatemia

Abstract

Objective: This study aims to explore and analyze the clinical efficacy of Sevelamer Carbonate tablets in combination with hemodialysis for treating uremia with hyperphosphatemia. Methods: Participants who suffered from hyperphosphatemia were included. A total of 144 participants were assigned to a single dialysis group (n = 70), treated with routine hemodialysis, and a drug group (n = 74), treated with Sevelamer Carbonate tablets combined with routine hemodialysis according to different therapy schemes. All the participants did not fall off. The indexes of renal function, lipid metabolism, and bone metabolism were compared between the two groups before and after therapy. Results: After two-week therapy, notably lower indicators of creatinine, urea nitrogen and uric acid for the drug group versus the single dialysis group (p < 0.05), in terms of lipid metabolism indicators, notably lower total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) concentrations for the drug group versus the single dialysis group (p < 0.05). Besides, as to bone metabolism indicators, intact Parathyroid Hormone (iPTH) (p > 0.05), alkaline phosphatase (ALP) (p < 0.05), and phosphorus (p < 0.05) in the drug group were lower, and calcium (p < 0.05) was higher than those in the single dialysis group. Conclusions: Sevelamer Carbonate tablets combined with hemodialysis can effectively improve renal function, lipid metabolism, and bone metabolism in patients with uremia and hyperphosphatemia.